On March 2, 2021 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, reported their collaboration with Immunitas Therapeutics, Inc. (www.immunitastx.com) for the development of a systems pharmacology model for an oncology pathway with complex receptor-ligand dynamics (Press release, Applied BioMath, MAR 2, 2021, View Source [SID1234575975]). The model will be used to understand the importance of targeting multiple receptors simultaneously and will inform the optimal therapeutic modality. "Efficiently translating early research into a clinical candidate is a top priority at Immunitas," said Tarek Samad, CSO of Immunitas. "We look forward to leveraging Applied BioMath’s mathematical models to better understand the best path forward for this therapeutic program."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. "Our proprietary software platforms and high-performance computing were designed to model biological systems and enable us to compare various dosing regimens more quickly than traditional approaches," said John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "This ability early on in therapeutic R&D is critical and we are excited to collaborate with Immunitas on this project."